The comparative effect of capecitabine and tegafur/gimeracil/oteracil(S-1) on advanced colorectal cancer
10.3760/cma.j.issn.1008-6706.2013.06.012
- VernacularTitle:卡培他滨与替吉奥治疗晚期大肠癌疗效比较
- Author:
Dongsheng SUN
;
Guirong ZHANG
;
Liguo MA
;
Yuhuan ZOU
- Publication Type:Journal Article
- Keywords:
Colorectal neoplasms;
Capecitabine;
Gimeracil and Oteracil
- From:
Chinese Journal of Primary Medicine and Pharmacy
2013;20(6):826-827
- CountryChina
- Language:Chinese
-
Abstract:
Objective To test comparative effect of capecitabine and S-1 (Tegafur/gimeracil/oteracil) on advanced colorectal cancer.Methods 106 cases of advanced colorectal cancer in our hospital oncology were collected and randomly divided into 2 groups:capecitabine group (52 cases) and S-1 group (54 cases).The chemotherapy effect and adverse effect of 2 groups were collected.Results After one treatment period,3 cases of complete remission,19 cases of partial remission,15 cases of stable disease,15 cases of disease progression,efficient rate of 42.3％and control rate of 71.2％ were observed in capecitabine group.5 cases of complete remission,21cases of partial remission,19 cases of stable disease,9 cases of disease progression and efficient rate of 48.1％ and control rate of 83.3％ were observed in S-1 group.There were no significant differences in efficient rate,control rate adverse effect rate and survival time between 2 groups(P ＞ 0.05).Conclusion Capecitabine and S-1 are both safe and effective in treatment of advanced colorectal cancer.
